NO20014657L - Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol - Google Patents
Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) CholesterolInfo
- Publication number
- NO20014657L NO20014657L NO20014657A NO20014657A NO20014657L NO 20014657 L NO20014657 L NO 20014657L NO 20014657 A NO20014657 A NO 20014657A NO 20014657 A NO20014657 A NO 20014657A NO 20014657 L NO20014657 L NO 20014657L
- Authority
- NO
- Norway
- Prior art keywords
- cholesterol
- density lipoprotein
- verylow
- vldl
- apolipoprotein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/277,401 US7008776B1 (en) | 1996-12-06 | 1999-03-26 | Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol |
PCT/US2000/007870 WO2000057837A2 (en) | 1999-03-26 | 2000-03-24 | Compositions and methods for effecting the levels of cholesterol |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20014657D0 NO20014657D0 (en) | 2001-09-25 |
NO20014657L true NO20014657L (en) | 2001-11-21 |
NO331779B1 NO331779B1 (en) | 2012-03-26 |
Family
ID=23060703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014657A NO331779B1 (en) | 1999-03-26 | 2001-09-25 | Methods for determining whether a test compound can inhibit the enzymatic reaction between the LIPG polypeptide and HDL cholesterol and apolipoprotein A1 or promote the enzymatic reaction between the LIPG polypeptide and VLDL cholesterol or LDL cholesterol |
NO20100214A NO331784B1 (en) | 1999-03-26 | 2010-02-11 | Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20100214A NO331784B1 (en) | 1999-03-26 | 2010-02-11 | Use of a ribozyme for the preparation of a composition capable of reducing the enzymatic activity of LIPG in a patient. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1171078A4 (en) |
JP (1) | JP2002540127A (en) |
KR (2) | KR20050044812A (en) |
AU (1) | AU776684B2 (en) |
BR (1) | BR0009333A (en) |
CA (1) | CA2363486C (en) |
HK (1) | HK1043309A1 (en) |
IL (2) | IL145526A0 (en) |
MX (1) | MXPA01009727A (en) |
NO (2) | NO331779B1 (en) |
NZ (2) | NZ531180A (en) |
WO (1) | WO2000057837A2 (en) |
ZA (1) | ZA200107598B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507808B2 (en) * | 2002-12-12 | 2009-03-24 | Isis Pharmaceuticals, Inc. | Modulation of endothelial lipase expression |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
US8921329B2 (en) | 2008-12-04 | 2014-12-30 | Curna, Inc. | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO |
US8927511B2 (en) | 2008-12-04 | 2015-01-06 | Curna, Inc. | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
DK2396038T3 (en) | 2009-02-12 | 2016-02-01 | Curna Inc | TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF |
EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
WO2010129861A2 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
WO2010135695A2 (en) | 2009-05-22 | 2010-11-25 | Curna, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
US8791085B2 (en) | 2009-05-28 | 2014-07-29 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
KR101702689B1 (en) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
EP2443237B1 (en) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
WO2010151671A2 (en) | 2009-06-24 | 2010-12-29 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011017516A2 (en) | 2009-08-05 | 2011-02-10 | Curna, Inc. | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
CA2770104C (en) | 2009-08-11 | 2019-03-19 | Opko Curna, Llc | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
JP5943836B2 (en) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | Treatment of CHIP-related diseases by inhibition of natural antisense transcripts on 'HSP70 interacting protein C-terminus' (CHIP) |
CA2771172C (en) | 2009-08-25 | 2021-11-30 | Opko Curna, Llc | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
NO2480669T3 (en) | 2009-09-25 | 2018-04-07 | ||
JP6025567B2 (en) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー,インコーポレイテッド | Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1) |
JP6031356B2 (en) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2. |
EP2516648B1 (en) | 2009-12-23 | 2017-11-08 | CuRNA, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
KR101853508B1 (en) | 2009-12-29 | 2018-06-20 | 큐알엔에이, 인크. | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 |
CN102791862B (en) | 2009-12-31 | 2017-04-05 | 库尔纳公司 | IRS2 relevant diseases are treated by suppressing the natural antisense transcript of insulin receptor substrate2 (IRS2) and transcription factor E3 (TFE3) |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
CN102822342B (en) | 2010-01-06 | 2017-05-10 | 库尔纳公司 | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
US9200277B2 (en) | 2010-01-11 | 2015-12-01 | Curna, Inc. | Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG |
US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
EP2539452B1 (en) | 2010-02-22 | 2016-07-27 | CuRNA, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
KR101877065B1 (en) | 2010-04-02 | 2018-07-10 | 큐알엔에이, 인크. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
RU2610661C2 (en) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
JP2013525483A (en) | 2010-05-03 | 2013-06-20 | カッパーアールエヌエー,インコーポレイテッド | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcripts against sirtuin (SIRT) |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
WO2011150007A2 (en) | 2010-05-26 | 2011-12-01 | Opko Curna Llc | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
RU2588654C2 (en) | 2010-06-23 | 2016-07-10 | Курна, Инк. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
EP2593547B1 (en) | 2010-07-14 | 2017-11-15 | CuRNA, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
CN103210086B (en) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4) |
CN103180445B (en) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA) |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
JP6071893B2 (en) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG |
CN103620036B (en) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN) |
CN103874486A (en) | 2011-09-06 | 2014-06-18 | 库尔纳公司 | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
TR201815503T4 (en) | 2012-03-15 | 2018-11-21 | Curna Inc | Treatment of brain-mediated neurotrophic factor (bknf) related diseases by inhibition of the native antisense transcript to bknf. |
CN102628060A (en) * | 2012-03-22 | 2012-08-08 | 北京济福霖生物技术有限公司 | Production method of low-fat milk |
JP6362268B2 (en) | 2012-11-05 | 2018-07-25 | 塩野義製薬株式会社 | Method for evaluating drug efficacy and screening method for EL activity inhibitory substance having therapeutic or preventive effect on diseases associated with EL activity |
BR112015022009A2 (en) | 2013-03-14 | 2017-08-29 | Shionogi & Co | MONOCLONAL ANTIBODY, INHIBITING THE ENZYME ACTIVITY OF VASCULAR ENDOTHELIAL LIPASE |
TWI688575B (en) | 2014-09-11 | 2020-03-21 | 日商塩野義製藥股份有限公司 | Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase |
WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
JPWO2023008337A1 (en) * | 2021-07-26 | 2023-02-02 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU679525B2 (en) * | 1992-12-04 | 1997-07-03 | Innovir Laboratories, Inc. | Regulatable nucleic acid therapeutic and methods of use thereof |
DE69732789T2 (en) * | 1996-12-06 | 2005-08-11 | Aventis Pharmaceuticals Inc. | HUMAN LIPASE-LIKE GENE GENE-CODED POLYPEPTIDES, AND COMPOSITIONS AND METHODS |
AU1941899A (en) * | 1997-12-19 | 1999-07-12 | Progenitor, Inc. | A lipase expressed in endothelial cells and methods for its use |
-
2000
- 2000-03-24 EP EP00918362A patent/EP1171078A4/en not_active Ceased
- 2000-03-24 CA CA2363486A patent/CA2363486C/en not_active Expired - Fee Related
- 2000-03-24 JP JP2000607588A patent/JP2002540127A/en active Pending
- 2000-03-24 IL IL14552600A patent/IL145526A0/en unknown
- 2000-03-24 AU AU39187/00A patent/AU776684B2/en not_active Ceased
- 2000-03-24 KR KR1020057005114A patent/KR20050044812A/en active Search and Examination
- 2000-03-24 MX MXPA01009727A patent/MXPA01009727A/en active IP Right Grant
- 2000-03-24 WO PCT/US2000/007870 patent/WO2000057837A2/en active IP Right Grant
- 2000-03-24 BR BR0009333-5A patent/BR0009333A/en not_active Application Discontinuation
- 2000-03-24 NZ NZ531180A patent/NZ531180A/en not_active IP Right Cessation
- 2000-03-24 KR KR1020017012300A patent/KR100887164B1/en not_active IP Right Cessation
- 2000-03-24 NZ NZ51435000A patent/NZ514350A/en not_active IP Right Cessation
-
2001
- 2001-09-14 ZA ZA200107598A patent/ZA200107598B/en unknown
- 2001-09-20 IL IL145526A patent/IL145526A/en not_active IP Right Cessation
- 2001-09-25 NO NO20014657A patent/NO331779B1/en not_active IP Right Cessation
-
2002
- 2002-06-28 HK HK02104818.0A patent/HK1043309A1/en unknown
-
2010
- 2010-02-11 NO NO20100214A patent/NO331784B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200107598B (en) | 2003-05-28 |
NO331779B1 (en) | 2012-03-26 |
HK1043309A1 (en) | 2002-09-13 |
NZ531180A (en) | 2005-06-24 |
CA2363486A1 (en) | 2000-10-05 |
CA2363486C (en) | 2012-12-18 |
KR20020029651A (en) | 2002-04-19 |
MXPA01009727A (en) | 2002-07-22 |
EP1171078A4 (en) | 2002-11-06 |
BR0009333A (en) | 2002-01-08 |
KR20050044812A (en) | 2005-05-12 |
IL145526A (en) | 2010-11-30 |
NO20014657D0 (en) | 2001-09-25 |
IL145526A0 (en) | 2002-06-30 |
NO20100214L (en) | 2001-11-21 |
NZ514350A (en) | 2004-12-24 |
KR100887164B1 (en) | 2009-03-10 |
WO2000057837A2 (en) | 2000-10-05 |
AU3918700A (en) | 2000-10-16 |
WO2000057837A8 (en) | 2001-09-27 |
NO331784B1 (en) | 2012-03-26 |
WO2000057837A3 (en) | 2001-01-25 |
EP1171078A2 (en) | 2002-01-16 |
WO2000057837A9 (en) | 2001-10-18 |
JP2002540127A (en) | 2002-11-26 |
AU776684B2 (en) | 2004-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014657L (en) | Preparations and Methods to Affect High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein A1, Verylow Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol | |
NO20016114L (en) | Preparations and Methods to Increase Cholesterol Elevation and Raise HDL Using ATP Binding Cartridge Carrier Protein ABC1 | |
AU1856997A (en) | Method for raising hdl cholesterol levels | |
AU2001241000A1 (en) | System and method for computer searching | |
AU2585301A (en) | System and method for trusted self-billing for utilities | |
AU2001275539A1 (en) | Method for authenticating and securing integrated bookstore entries | |
AU2001245401A1 (en) | Hydrazones and analogs as cholesterol lowering agents | |
AU2001266578A1 (en) | System and method for providing access to forms and maintaining the data used tocomplete the forms | |
NO20014029D0 (en) | Organic sol and solid compound based on cerium oxide and an amphiphilic compound and process for preparation | |
NO20020779L (en) | Methods, preparations and kits to promote healing of central nervous system damage | |
EP1342792A4 (en) | Test piece for assaying high density lipoprotein (hdl) cholesterol | |
EP1212065A4 (en) | Compositions and methods for raising hdl cholesterol levels | |
AU3239800A (en) | Method and apparatus for improving access to literature | |
NO20004104D0 (en) | Preparations comprising viruses and methods for concentrating virus preparations | |
WO2002044989A8 (en) | Method and system for dynamically maintaining internet associations | |
AU4880801A (en) | System and method for supporting businesses | |
AU2001278926A1 (en) | Attachments for support members and methods therefor | |
TWI319009B (en) | Pretreatment method of samples for cholesterol quantitation, and quantitation method of cholesterol in specific lipoprotein by the use of the pretreatme | |
DE69931279D1 (en) | METHOD AND COMPOSITIONS FOR REDUCING THE CHOLESTEROL MIRROR IN PLASMA | |
AU1960600A (en) | Method and apparatus for minimizing differential power attacks on processors | |
NO20005433D0 (en) | Human BMP-7 promoter and method to explore bone related substance using the same | |
AU2001249123A1 (en) | System and method for providing computer network search services | |
AU2001268601A1 (en) | Methods and apparatus for reducing vibrations induced within fan assemblies | |
EP1059579A3 (en) | Information processor and method for switching register files | |
AU6595700A (en) | Method and apparatus for operating virtual computer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |